{"id":3049,"date":"2016-07-15T06:30:00","date_gmt":"2016-07-15T06:30:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/xvivo-perfusion-interim-report-january-june-2016\/"},"modified":"2016-07-15T06:30:00","modified_gmt":"2016-07-15T06:30:00","slug":"xvivo-perfusion-interim-report-january-june-2016","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-interim-report-january-june-2016\/","title":{"rendered":"XVIVO Perfusion Interim report January \u2013 June 2016"},"content":{"rendered":"
ACQUISITION OF VIVOLINE STRENGTHENS XVIVO\u2019S PRODUCT AND R&D PORTFOLIO<\/strong><\/div>\n

SECOND QUARTER 2016 (APR \u2013 JUN)<\/span><\/p>\n

\u2022 Net sales in the quarter amounted to SEK 34.5 (29.1) million, corresponding to an increase of 18 percent. Net sales of non-Durable goods* in the quarter amounted to SEK 29.8 (27.4) million, corresponding to an increase of 9 percent in SEK and 11 percent in local currency.
\u2022 Operating income before depreciation and amortization (EBITDA) excluding one-time expenses increased by 51 percent and amounted to SEK 6.9 (4.6) million, corresponding to an EBITDA margin of 20 percent. One-time expenses of SEK 2.2 million related to the Nasdaq Stockholm main market listing and the public offer for Vivoline have been charged against the quarter. EBITDA amounted to SEK 4.8 (4.6) million, corresponding to an EBITDA margin of 14 percent.
\u2022 Net income amounted to SEK 1.5 (1.0) million, resulting in earnings per share of SEK 0.07 (0.05), affected by amortization and depreciation of SEK 3.1 (2.9) million.
\u2022 Cash flow from operating activities was SEK 8.1 (8.8) million.
\u2022 Total sales from warm perfusion (STEEN Solution\u2122, products and services related to the use of the XPS\u2122 and XPS\u2122) accounted for 42 (39) percent of the total sales.
\u2022 3 XPS\u2122 contracts were signed in the USA during the quarter, whereof 2 were shipped.
\u2022 During the quarter XVIVO Perfusion acquired 97 percent of the shares and 99 percent of the 2015\/2016 warrants in the listed company Vivoline Medical AB. The combined company creates more resources and competence to take Professor Stig Steen\u2019s world-leading research in the field of heart transplantation to a commercial phase. The acquisition also strengthens XVIVO Perfusion\u2019s market position in the field of lung transplantation.
\u2022 The first patient in the clinical study with PrimECC\u00ae<\/sup> was included. PrimECC\u00ae<\/sup> is a CE marked and patent-protected product, developed to prime the heart-lung machine before open heart surgery.
\u2022 STEEN Solution\u2122 was used for the first time to give localized delivery of a chemotherapy agent to a patient suffering from metastatic lung sarcoma through In-Vivo Lung Perfusion (IVLP).
\u2022 XVIVO Perfusion\u2019s share warrant program 2016\/2018, which was offered to employees, was fully subscribed.<\/span><\/p>\n

THE PERIOD 2016 (JAN \u2013 JUN)<\/span><\/p>\n

\u2022 Net sales in the period amounted to SEK 68.0 (60.9) million, corresponding to an increase of 12 percent. Net sales of non-Durable goods* in the period amounted to SEK 58.8 (52.5) million, corresponding to an increase of 12 percent in SEK and 13 percent in local currency.
\u2022 Operating income before depreciation and amortization (EBITDA) excluding one-time expenses increased by 56 percent and amounted to SEK 14.2 (9.1) million, corresponding to an EBITDA margin of 21 percent. One-time expenses of SEK 4.6 million related to the Nasdaq Stockholm main market listing and the public offer for Vivoline have been charged against the period. EBITDA amounted to SEK 9.6 (7.5) million, corresponding to an EBITDA margin of 14 percent.
\u2022 Net income amounted to SEK 2.6 (1.0) million, resulting in earnings per share of SEK 0.12 (0.05), affected by amortization and depreciation of SEK 6.2 (5.6) million.
\u2022 Cash flow from operating activities was SEK 13.3 (2.9) million. Cash at bank increased by SEK 0.6 million to SEK 41.8 million during the period, even though the Vivoline acquisition affected cash with SEK -7.6 million.
\u2022 Total sales from warm perfusion (STEEN Solution\u2122, products and services related to the use of the XPS\u2122 and XPS\u2122) accounted for 41 (42) percent of the total sales.
\u2022 During the period 5 XPS\u2122 were sold, of which 2 to Europe and 3 to the US. France and Switzerland were new countries that got access to the XPS\u2122 during the period.
\u2022 XVIVO Perfusion AB\u2019s shares were admitted for trading on Nasdaq First North Premier 8 February 2016. The company's shares will continue trading with the same short name and ISIN code.<\/span><\/p>\n

SIGNIFICANT EVENTS AFTER THE END OF THE QUARTER <\/span><\/p>\n

\u2022 On July 14 the extended acceptance period for the offer for the shares and warrants of series 2015\/2016 in Vivoline Medical AB was closed. During the extended acceptance period further 179,097 shares and 28,155 warrants were accepted, whereby XVIVO Perfusion became the owner of 98.6 percent of the shares and 99.6 percent of the warrants. Therefore, the Board decided to issue 30,065 new shares in XVIVO Perfusion as payment for the acquired shares and warrants.
\u2022 At the time of publication of this report, 39 clinics have access to the XPS\u2122 and LS-1**, including 20 clinics in the US and 19 clinics in Europe and the rest of the world.<\/span><\/p>\n

CONFERENCE CALL<\/span><\/p>\n

CEO Magnus Nilsson will present the report in a conference call at 2 p.m. CET on Friday, July 15, 2016. Telephone: +44 (0) 1452 555566, enter code 41101325.<\/span><\/p>\n

July 15, 2016
Gothenburg
XVIVO Perfusion AB (publ)
Magnus Nilsson, CEO<\/span>\u00a0<\/p>\n

* Durable goods are sales revenues from the XPS\u2122.
** LS-1 is the Vivoline EVLP machine.<\/span><\/p>\n

\n

For further information please contact:<\/span><\/p>\n

Christoffer Rosenblad, CFO, +1 720 616 2101, christoffer.rosenblad@xvivoperfusion.com
Magnus Nilsson, CEO, +46 31 788 2150, magnus.nilsson@xvivoperfusion.com<\/span>
For further information on XVIVO Perfusion\u2019s business, please refer to the company\u2019s website, www.xvivoperfusion.com<\/span><\/p>\n

The information was submitted for publication on\u00a0July15, 2016\u00a0at 8:30 a.m.<\/span><\/p>\n

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.<\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

ACQUISITION OF VIVOLINE STRENGTHENS XVIVO\u2019S PRODUCT AND R&D PORTFOLIO SECOND QUARTER 2016 (APR \u2013 JUN) \u2022 Net sales in the…<\/p>\n","protected":false},"template":"","class_list":["post-3049","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-en","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-regulatory-vpml","mfn-news-tag-mfn-report","mfn-news-tag-mfn-report-interim","mfn-news-tag-mfn-report-interim-q2"],"acf":[],"yoast_head":"\nXVIVO Perfusion Interim report January \u2013 June 2016 - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-interim-report-january-june-2016\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"XVIVO Perfusion Interim report January \u2013 June 2016 - XVIVO\" \/>\n<meta property=\"og:description\" content=\"ACQUISITION OF VIVOLINE STRENGTHENS XVIVO\u2019S PRODUCT AND R&D PORTFOLIO SECOND QUARTER 2016 (APR \u2013 JUN) \u2022 Net sales in the...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-interim-report-january-june-2016\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusion-interim-report-january-june-2016\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusion-interim-report-january-june-2016\\\/\",\"name\":\"XVIVO Perfusion Interim report January \u2013 June 2016 - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2016-07-15T06:30:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusion-interim-report-january-june-2016\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusion-interim-report-january-june-2016\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusion-interim-report-january-june-2016\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"XVIVO Perfusion Interim report January \u2013 June 2016\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"XVIVO Perfusion Interim report January \u2013 June 2016 - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-interim-report-january-june-2016\/","og_locale":"en_US","og_type":"article","og_title":"XVIVO Perfusion Interim report January \u2013 June 2016 - XVIVO","og_description":"ACQUISITION OF VIVOLINE STRENGTHENS XVIVO\u2019S PRODUCT AND R&D PORTFOLIO SECOND QUARTER 2016 (APR \u2013 JUN) \u2022 Net sales in the...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-interim-report-january-june-2016\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-interim-report-january-june-2016\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-interim-report-january-june-2016\/","name":"XVIVO Perfusion Interim report January \u2013 June 2016 - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2016-07-15T06:30:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-interim-report-january-june-2016\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-interim-report-january-june-2016\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-interim-report-january-june-2016\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"XVIVO Perfusion Interim report January \u2013 June 2016"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/3049","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=3049"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}